A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate. Issue 3 (14th August 2021)

• Record Type: Journal Article
• Authors: Chalabi-Dchar, Mounira; Fenouil, Tanguy; Machon, Christelle; Vincent, Anne; Catez, Frédéric; Marcel, Virginie; Mertani, Hichem C; Saurin, Jean-Christophe; Bouvet, Philippe; Guitton, Jérôme; Venezia, Nicole Dalla; Diaz, Jean-Jacques
• Is Part Of: NAR cancer. Volumer 3:Issue 3(2021)
• Publication Date: 2021-08-14
• Subjects: Cancer -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 616.994
• DOI: 10.1093/narcan/zcab032
• Languages: English
• ISSNs: 2632-8674

Abstract

Abstract: 5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat patients with solid tumours, such as colorectal and pancreatic cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related death and half of patients experience tumour recurrence. Used for over 60 years, 5-FU was long thought to exert its cytotoxic effects by altering DNA metabolism. However, 5-FU mode of action is more complex than previously anticipated since 5-FU is an extrinsic source of RNA modifications through its ability to be incorporated into most classes of RNA. In particular, a recent report highlighted that, by its integration into the most abundant RNA, namely ribosomal RNA (rRNA), 5-FU creates fluorinated active ribosomes and induces translational reprogramming. Here, we review the historical knowledge of 5-FU mode of action and discuss progress in the field of 5-FU-induced RNA modifications. The case of rRNA, the essential component of ribosome and translational activity, and the plasticity of which was recently associated with cancer, is highlighted. We propose that translational reprogramming, induced by 5-FU integration in ribosomes, contributes to 5-FU-driven cell plasticity and ultimately to relapse. Graphical Abstract: